On September 21, CSPC PHARMA rose 3.02% in regular trading, trading at HK$9.18/share, with turnover of HK$34.34 million. The stock opened higher and extended gains in the early session, supported by a confluence of positive fundamental and pipeline developments.
On the earnings front, the company reported H1 revenue of RMB 18.594 billion, up 40.1% year-over-year, with adjusted net profit surging 165.8% to RMB 6.164 billion. Gross margin expanded to 76.2% from 65.6%, driven by a higher revenue mix from the finished drug segment. Operating cash inflow reached RMB 10.89 billion, compared with RMB 3.187 billion in the prior year period. Out-licensing income contributed RMB 589 million, emerging as a key second growth curve.
On the pipeline side, CSPC has delivered a rapid succession of milestones: its ADC drug SYS6010 received Breakthrough Therapy Designation from China NMPA for both NSCLC and head-and-neck squamous carcinoma; SYH2069 entered Phase II trials for both type 2 diabetes and obesity; and SYH2092, an amylin receptor agonist for weight management, initiated Phase I trials. CLSA reiterated a High Conviction Outperform rating with a HK$19 target price.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments